Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021649 | 1.00 | ITGB3 (0.55) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL4889870 | 1.00 | ITGB3 (0.55) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL14021750 | 0.92 | PPARG (0.55) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL4597517 | 0.92 | PPARG (0.55) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL4887436 | 0.92 | PPARG (0.55) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL9077727 | 0.89 | PPARG (0.59) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL9077724 | 0.89 | PPARG (0.59) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3867713 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3867720 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL4595997 | 0.85 | ACE (0.51) | ITGB3ITGA2BPPARGPPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | ITGB3 3939/4885ITGA2B 4038/4885PPARG 213/4885 |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | ITGB3 3939/4885ITGA2B 4038/4885PPARG 213/4885 |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, AADAT, FABP4 | ITGB3 3939/4885ITGA2B 4038/4885PPARG 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.